See more : Pirelli & C. S.p.A. (PIRC.MI) Income Statement Analysis – Financial Results
Complete financial analysis of PROCEPT BioRobotics Corporation (PRCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PROCEPT BioRobotics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- China Digital Video Holdings Limited (8280.HK) Income Statement Analysis – Financial Results
- Keyware Solutions Inc. (3799.T) Income Statement Analysis – Financial Results
- Resource Capital Gold Corp. (GDPEF) Income Statement Analysis – Financial Results
- China Vanadium Titano-Magnetite Mining Company Limited (0893.HK) Income Statement Analysis – Financial Results
- Swvl Holdings Corp. (SWVL) Income Statement Analysis – Financial Results
PROCEPT BioRobotics Corporation (PRCT)
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Cost of Revenue | 65.14M | 37.93M | 18.61M | 8.97M | 8.05M |
| Gross Profit | 71.05M | 37.09M | 15.87M | -1.26M | -1.89M |
| Gross Profit Ratio | 52.17% | 49.44% | 46.02% | -16.26% | -30.56% |
| Research & Development | 48.45M | 28.98M | 18.99M | 16.28M | 13.15M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.77M | 88.83M | 51.04M | 30.27M | 28.52M |
| Other Expenses | 0.00 | -203.00K | -154.00K | -25.00K | -46.00K |
| Operating Expenses | 180.22M | 117.81M | 70.03M | 46.55M | 41.67M |
| Cost & Expenses | 245.36M | 155.74M | 88.64M | 55.52M | 49.72M |
| Interest Income | 7.55M | 2.01M | 121.00K | 184.00K | 1.15M |
| Interest Expense | 4.00M | 5.18M | 5.81M | 5.26M | 724.00K |
| Depreciation & Amortization | 3.81M | 4.32M | 2.98M | 2.70M | 1.49M |
| EBITDA | -98.10M | -77.65M | -51.06M | -45.06M | -39.76M |
| EBITDA Ratio | -72.03% | -104.93% | -156.77% | -580.32% | -663.85% |
| Operating Income | -109.17M | -80.72M | -54.16M | -47.80M | -43.55M |
| Operating Income Ratio | -80.16% | -107.61% | -157.12% | -619.44% | -705.95% |
| Total Other Income/Expenses | 3.27M | -6.43M | -5.69M | -5.22M | 1.58M |
| Income Before Tax | -105.90M | -87.15M | -59.85M | -53.02M | -41.98M |
| Income Before Tax Ratio | -77.76% | -116.18% | -173.62% | -687.04% | -680.42% |
| Income Tax Expense | 0.00 | 6.43M | 2.53M | 5.24M | 678.00K |
| Net Income | -105.90M | -93.58M | -62.38M | -58.26M | -42.65M |
| Net Income Ratio | -77.76% | -124.76% | -180.96% | -754.89% | -691.41% |
| EPS | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| EPS Diluted | -2.24 | -2.11 | -1.43 | -1.35 | -0.99 |
| Weighted Avg Shares Out | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
| Weighted Avg Shares Out (Dil) | 47.26M | 44.40M | 43.68M | 43.25M | 43.25M |
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan...
3 Robotics Stocks to Sell in August Before They Crash & Burn
While the global industrial automation market is poised for a CAGR of 8.3% between 2024 and 2031, according to SkyQuest, it bears winnowing out the particulars of the market, including identifying robotics stocks to sell. With signals pointing to global...
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Surgical robotics company PROCEPT BioRobotics Co. NASDAQ: PRCT developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia (BPH) among aging men. The company went public during the special purpose acquisition company (SPAC) mania in 2021.
PROCEPT BioRobotics Corporation (PRCT) Q2 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive VP, Chief Commercial...
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.56 per share a year ago.
PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended...
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the...
You've Been Warned! 3 Robotics Stocks to Buy Now or Regret Forever.
Right now, growth investors are focused primarily on opportunities in the semiconductors and artificial intelligence stocks space. That's understandable, given how fast technology is advancing in those areas right now.
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has...
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the...
Source: https://incomestatements.info
Category: Stock Reports